EUCTR2005-000664-51-AT进行中（未招募）不适用
A RANDOMIZED DOUBLE-BLIND PARALLELL GROUP CLINICAL STUDY OF XENETIX 300 VERSUS VISIPAQUE 270 IN MULTISLICE CT PEDIATRIC INDICATIONS - PEDIATRIC MSCT
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- GUERBET
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Child aged between 1 and 16 years, having an MSCT with contrast product injection planned
- •- Patient planned for a blood test in the 24 hours preceding the scan
- •- Female patient with child bearing potential with contracetion or who has a negative BetaHCG test
- •- Parents (and the child if aged over 12 years) having given their consent to participate in the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients who has received diuretic or biguanide treatment during 48 hours preceding the MSCT
- •- Patients having received an iodinated contrast agent during the 48 hours preceding the MSCT
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED DOUBLE-BLIND PARALLELL GROUP CLINICAL STUDY OF XENETIX 300 VERSUS VISIPAQUE 270 IN MULTISLICE CT PEDIATRIC INDICATIONS - XENETIX 300 VS VISIPAQUE 270 IN MSCT IN CHILDREPatients requiring MSCT with contrast medium injection for diagnosisEUCTR2005-000664-51-GBGUERBET142
尚未招募
不适用
A Randomized, Clinical Study to evaluate Efficacy and Safety of ONLP-15 in the Management of Cardio Vascular disease risk factorsCTRI/2022/02/039981Olene Life Sciences Private Limited
尚未招募
2 期
To observe the effect of Ayurvedic medicine for the treatment of Obesity with abnormal lipid profileCTRI/2022/01/039315Desh Bhagat University
已完成
4 期
Efficacy and Safety of Flabonoid in subjects with Metabolic syndromeCTRI/2015/11/006366Generix Lifesciences Pvt Ltd
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 100000004871EUCTR2021-006069-39-DESanofi-Aventis Recherche & Développement190